Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
- Details
- Category: Novartis
Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the efficacy of KAF156 in combination with a new, improved formulation of the existing antimalarial lumefantrine.
Lyfebulb-Novo Nordisk Innovation Award 2017
- Details
- Category: Business
The Lyfebulb-Novo Nordisk Innovation Summit 2017 will recognize and empower international Patient Entrepreneurs with big ideas that disrupt the future of diabetes management. Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. The aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes.
Repatha® (evolocumab) phase 3 cognitive function study results published in the New England Journal of Medicine
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that the New England Journal of Medicine (NEJM) published results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER).
Bristol-Myers Squibb announces topline results from CheckMate -214
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma.
Boehringer Ingelheim achieves good growth in the first half of 2017
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has delivered positive results for the first half of 2017. Net sales increased by 24 per cent on the same period in the previous year to 9.2 billion euros after adjustment for currency effects (+27 per cent in euro terms).(1) In the first half of the year, Boehringer Ingelheim's figures for the first time included the net sales of Sanofi’s animal health business, Merial, which was acquired at the start of the year.
FDA Advisory Committee votes in favor of XELJANZ® (tofacitinib citrate) for the treatment of active psoriatic arthritis
- Details
- Category: Pfizer
Pfizer Inc. announced that the United States Food and Drug Administration's (FDA) Arthritis Advisory Committee (AAC) voted 10 to 1 to recommend approval of the proposed dose of tofacitinib for the treatment of adult patients with active psoriatic arthritis (PsA). Pfizer submitted supplemental new drug applications (sNDAs) for XELJANZ® 5 mg twice daily (BID) and XELJANZ® XR extended release 11 mg once daily (QD) for this pending indication.
Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and IFM Therapeutics (IFM) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.
More Pharma News ...
- US FDA accepts regulatory submission for acalabrutinib and grants Priority Review
- Roche reports strong performance in the first half of 2017
- Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration
- AstraZeneca and Merck establish strategic oncology collaboration
- Johnson & Johnson announces encouraging first-in-human clinical data for investigational HIV preventive vaccine
- Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
- Pfizer announces positive top-line results from the comparative REFLECTIONS B7391003 study for PF-06439535, a potential biosimilar to Avastin® (bevacizumab)